Affinia Therapeutics is at the forefront of advancing gene therapy, particularly through its proprietary platform known as Affinia Rationally-designed Therapies (ART). This innovative approach focuses on re-engineering the essential components of gene therapy, including the capsid, therapeutic payload, and manufacturing processes. By utilizing advanced tools such as artificial intelligence and structural modeling, Affinia aims to enhance the targeted delivery of genetic material to specific tissues, thereby improving the safety and efficacy of treatments. Their work emphasizes the development of novel adeno-associated virus (AAV) capsids that can effectively reach heart and nervous system tissues, which are often challenging to target with existing therapies.

The company is particularly focused on addressing diseases of the heart and nervous system, where they see significant potential for transformative treatments. Their ART platform allows for the design of capsids that can cross the blood-brain barrier and effectively deliver therapeutic payloads to neurons, a critical advancement for conditions like amyotrophic lateral sclerosis and Alzheimer’s disease. Additionally, Affinia is committed to innovating manufacturing processes to ensure high-quality, cost-effective gene therapies. By integrating these elements, Affinia Therapeutics is positioning itself to make a lasting impact on the treatment landscape for both rare and prevalent diseases.

United States

Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world.

Affinia Therapeutics

Company Details